TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02766114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carpal tunnel release through Mini Transverse Approach
Description: Carpal tunnel release through a transverse cosmetic small incision over the distal wrist crease.
Study: NCT00578474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacin otic solution
Description: 5 drops into the infected ear(s) twice daily (morning and evening) for 10 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study: NCT03367819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT01308476

Intervention type: PROCEDURE
Intervention: SMS reminder
Description: daily SMS in the SMS group to remind of treatment with tiotropium

Intervention type: PROCEDURE
Intervention: control group
Description: no daily SMS to remind of treatment with tiotropium
Study: NCT03367819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT01334658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification cataract surgery
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose-bicarbonate-Ringer Lactate (GBRL)
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced Salt Solution (BSS®)
Description: A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) \[500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)\] as a solution for irrigation during surgery.~All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation \[BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)\] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..).
Study: NCT02956226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinoids - 99% pure cannabinoids mix
Description: 99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olive oil and flavors solution.
Study: NCT03367819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT02956226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinoids - whole plant extract
Description: Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
Study: NCT01974310

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy & Intraocular gas fill

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy & Intraocular gas fill

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative face-down positioning
Study: NCT03506165

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Periodontal treatment
Description: oral hygiene instructions, periodontal debridement and removal of other etiologic factors
Study: NCT03852446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod HCL (F2) tablets
Description: The doses will be ascending per cohort from 600 mg to 2400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod base formulation
Description: Single oral administration of 1200 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The matching placebo doses will be ascending per cohort from 1 to 4 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indoximod HCL (F2) tablets
Description: Single oral administration of 1200 mg
Study: NCT03367819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03330873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: disposable balloon uterine stent
Description: The disposable balloon uterine stent is heart-shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to Foley catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: Foley catheter can partly separate the sides of uterus wall.
Study: NCT00591773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil and chlorthalidone
Description: Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorthalidone
Description: Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
Study: NCT01243957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: LY2216684: 18 mg po QD on Days 1, 2, and 3 and Days 25-27

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine: 60 mg po QD for 7 days (Days 4-10) then 20 mg po QD for 17 days (Days 11-27)
Study: NCT01250470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51/Survivin Peptide Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT02129803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Flow, 20 LPM (via Optiflow cannula)
Description: Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low FLow, 5 LPM (via Optiflow cannula)
Description: standard humidified wall medical air.
Study: NCT02455310

Intervention type: BEHAVIORAL
Intervention: Educational activities to improve dementia care
Description: The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.

Intervention type: BEHAVIORAL
Intervention: Educational activities to improve dementia care
Description: The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
Study: NCT02462967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR-MD-02
Description: GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR-MD-02
Description: GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for GR-MD-02
Study: NCT00577512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTPACE
Description: * Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4
Study: NCT02118909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Study: NCT00450814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03878576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: REFERENCE: white bread - BGL0 [RP]
Description: Determination of glycemic response after consumption of BGL0.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST: b-glucan enriched bread - BGL2 [IP1]
Description: Determination of glycemic response after consumption of BGL0.
Study: NCT04074317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAM9
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAM9
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAM9
Description: SC injection
Study: NCT03878576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST: b-glucan enriched bread - BGL3 [IP2]
Description: Determination of glycemic response after consumption of BGL0.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEST: b-glucan enriched bread - BGL4 [IP3]
Description: Determination of glycemic response after consumption of BGL0.
Study: NCT03478631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-nitrate dehydrated vegetable powder
Description: A mixed combination of vegetable powders that are naturally high in nitrate content, such as beet, spinach, and kale
Study: NCT04074317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAM9
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAM9
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRAM9
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin + Pramlintide
Description: Separate SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin + Pramlintide
Description: Separate SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin + Pramlintide
Description: Separate SC injections
Study: NCT03478631

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-nitrate dehydrated vegetable powder
Description: A mixed combination of vegetable powders that are naturally low in nitrate content, such as peas, tomato, broccoli, carrots, and brussel sprouts
Study: NCT03572465

Intervention type: DEVICE
Intervention: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)
Description: Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)

Intervention type: DEVICE
Intervention: Acoustic radiation force impulse (ARFI), magnetic resonance elastography (MRE)
Description: Acoustic Radiation Force Impulse (ARFI), Magnetic Resonance Elastography (MRE)
Study: NCT02427334

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: women will receive oral placebo for 14 days starting from the 15th day of menstruation
Study: NCT00804804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation and multiple rest
Description: To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation and multiple rest
Description: To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
Study: NCT04123405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Description: 600 mg tablet
Study: NCT00933543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Visonac PDT (MAL PDT)
Description: Cream application followed by illumination with red light.
Study: NCT04074317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin + Pramlintide
Description: Separate SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin + Pramlintide
Description: Separate SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin + Pramlintide
Description: Separate SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Description: SC injection
Study: NCT00423891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
Study: NCT02609022

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV-MG01
Description: 3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.~Two dose levels: low and high dose.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
Study: NCT03145441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb®
Description: CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
Study: NCT03926234

Intervention type: OTHER
Intervention: Four-level Chinese Emergency triage scale
Description: a four-level category system, i.e. life-threatening (Level I), emergent (Level II), urgent (Level III) and semi-urgent (Level IV) . This system contains critical indicators (cardiac arrest, shock, and apnea), high risk indicators (ACS and DKA), single objective indicators (SBP, RR, HR, and SpO2) and MEWS (synthesis indicator). According to patients' health care problems, patients are rated by nurses into one of the four mentioned levels.
Study: NCT02108821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
Study: NCT01414335

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: amino acid composition
Description: one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
Study: NCT02179996

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Three vaccine injections DTP-pertussis-Hib
Description: DTP-pertussis-Hib injections at two, three, four months after birth

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two vaccine injections DTP-pertussis-Hib
Description: DTP-pertussis-Hib injections are administered at two and four months after birth
Study: NCT02091791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traction sessions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traction sessions
Study: NCT00639834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDX-1342
Description: One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
Study: NCT04123405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Description: 600 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylcysteine
Description: 600 mg tablet
Study: NCT05117411

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA and pseudophakin cystoid edema
Description: Patients underwent OCT angiografia after cataract surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: OCTA and pseudophakin cystoid edema
Description: Patients underwent OCT angiografia after cataract surgery
Study: NCT01966965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIOLIN®
Description: PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NEDAX
Description: AS SPECIFIED AT THE LEAFLET
Study: NCT02886377

Intervention type: BIOLOGICAL
Intervention: blood test of anti-AQP4 antibody
Description: Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.

Intervention type: BIOLOGICAL
Intervention: blood test of anti-AQP4 antibody
Description: Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.

Intervention type: BIOLOGICAL
Intervention: blood test of anti-AQP4 antibody
Description: Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
Study: NCT03437785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-495 75mg
Description: CKD-495 75mg Tab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-495 150mg
Description: CKD-495 150mg Tab.
Study: NCT02716272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
Study: NCT00933543

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream (placebo)
Description: Cream application followed by illumination with red light.